Health knowledge made personal
Join this community!
› Share page:
Search posts:

New Class Of Cancer Drugs Could Work In Colon Cancers With Genetic Mmutation

Posted Apr 26 2011 8:44am

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

Working in cell lines from colorectal cancer patients, researchers found that a new class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.

About 15 percent of all colorectal cancers have what’s called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation.

Post a comment
Write a comment:

Related Searches